Orbital Therapeutics / BMS
BMS completed its acquisition in December 2025, obtaining OTX-201, a preclinical RNA-based in vivo CAR-T program for autoimmune disease. The filing establishes ownership and the disclosed development stage; it does not report human efficacy.
Corporate information
- Company entity
- Orbital Therapeutics / BMS
- Headquarters / principal office
- Cambridge, Massachusetts, USASelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2022 (public launch) ↗
- Ownership / capital status
- AcquiredNot verified
- Official corporate reference
- https://www.bms.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
BMS completed its acquisition in December 2025, obtaining OTX-201, a preclinical RNA-based in vivo CAR-T program for autoimmune disease. The filing establishes ownership and the disclosed development stage; it does not report human efficacy.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Primary corporate profile / legal-entity disclosure
- Official corporate website audit
- Founding / incorporation disclosure — scope stated in field
- Orbital company-managed LinkedIn location